-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Analysts Issue Forecasts for NewAmsterdam Pharma's FY2027 Earnings (NASDAQ:NAMS)
Analysts Issue Forecasts for NewAmsterdam Pharma's FY2027 Earnings (NASDAQ:NAMS)
NewAmsterdam Pharma (NASDAQ:NAMS – Get Rating) – Research analysts at William Blair issued their FY2027 earnings per share estimates for NewAmsterdam Pharma in a research report issued to clients and investors on Monday, January 23rd. William Blair analyst M. Phipps expects that the company will earn ($0.16) per share for the year. William Blair currently has a "Outperform" rating on the stock. The consensus estimate for NewAmsterdam Pharma's current full-year earnings is $0.27 per share.
Get NewAmsterdam Pharma alerts:Several other research analysts also recently commented on the company. Credit Suisse Group began coverage on NewAmsterdam Pharma in a research note on Friday, January 6th. They issued an "outperform" rating and a $21.00 target price for the company. Jefferies Financial Group initiated coverage on NewAmsterdam Pharma in a research report on Monday, December 19th. They issued a "buy" rating and a $24.00 price objective on the stock. Finally, SVB Leerink assumed coverage on NewAmsterdam Pharma in a research report on Tuesday, December 20th. They issued an "outperform" rating and a $19.00 price objective on the stock.
NewAmsterdam Pharma Stock Up 20.0 %
Shares of NewAmsterdam Pharma stock opened at $13.56 on Thursday. NewAmsterdam Pharma has a 1 year low of $7.52 and a 1 year high of $32.88. The company's fifty day simple moving average is $10.37.NewAmsterdam Pharma Company Profile
(Get Rating)
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, develops oral, non-statin medicines for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol (LDL-C). The company's lead product candidate is obicetrapib, an oral, low-dose cholesteryl ester transfer protein inhibitor that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C and preventing major adverse cardiovascular events.
Recommended Stories
- Get a free copy of the StockNews.com research report on NewAmsterdam Pharma (NAMS)
- Shopify Clears Cup-With-Handle Base: Can Momentum Continue?
- The Future Of E-Commerce: Analysis And New Data
- Chevron Delights Shareholders with $75 Billion in Share Buybacks
- Levi Strauss Is A Good Fit For Income Investors
- 3 Small Caps That Have Big Upside
Receive News & Ratings for NewAmsterdam Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewAmsterdam Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
NewAmsterdam Pharma (NASDAQ:NAMS – Get Rating) – Research analysts at William Blair issued their FY2027 earnings per share estimates for NewAmsterdam Pharma in a research report issued to clients and investors on Monday, January 23rd. William Blair analyst M. Phipps expects that the company will earn ($0.16) per share for the year. William Blair currently has a "Outperform" rating on the stock. The consensus estimate for NewAmsterdam Pharma's current full-year earnings is $0.27 per share.
NewAmsterdam Pharma(纳斯达克股票代码:NAMS — 获取评级)——威廉·布莱尔的研究分析师在1月23日星期一向客户和投资者发布的一份研究报告中公布了NewAmsterdam Pharma的 FY2027 每股收益估计。威廉·布莱尔分析师菲普斯预计,该公司今年的每股盈利(0.16美元)。威廉·布莱尔目前对该股的评级为 “跑赢大盘”。NewAmsterdam Pharma目前的全年收益的共识估计为每股0.27美元。
Several other research analysts also recently commented on the company. Credit Suisse Group began coverage on NewAmsterdam Pharma in a research note on Friday, January 6th. They issued an "outperform" rating and a $21.00 target price for the company. Jefferies Financial Group initiated coverage on NewAmsterdam Pharma in a research report on Monday, December 19th. They issued a "buy" rating and a $24.00 price objective on the stock. Finally, SVB Leerink assumed coverage on NewAmsterdam Pharma in a research report on Tuesday, December 20th. They issued an "outperform" rating and a $19.00 price objective on the stock.
其他几位研究分析师最近也对该公司发表了评论。瑞士信贷集团在1月6日星期五的一份研究报告中开始报道NewAmsterdam Pharma。他们为该公司发布了 “跑赢大盘” 评级和21.00美元的目标价格。杰富瑞金融集团在12月19日星期一的一份研究报告中开始报道NewAmsterdam Pharma。他们对该股发布了 “买入” 评级和24.00美元的目标价格。最后,SVB Leerink在12月20日星期二的一份研究报告中假设对NewAmsterdam Pharma进行了报道。他们对该股发布了 “跑赢大盘” 评级和19.00美元的目标股价。
NewAmsterdam Pharma Stock Up 20.0 %
新阿姆斯特丹制药公司股票上涨20.0%
NewAmsterdam Pharma Company Profile
新阿姆斯特丹制药公司简介
(Get Rating)
(获取评分)
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, develops oral, non-statin medicines for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol (LDL-C). The company's lead product candidate is obicetrapib, an oral, low-dose cholesteryl ester transfer protein inhibitor that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C and preventing major adverse cardiovascular events.
NewAmsterdam Pharma Company N.V. 是一家临床阶段的生物制药公司,为低密度脂蛋白胆固醇(LDL-C)残留升高的心血管疾病高风险患者开发口服非他汀类药物。该公司的主要候选产品是obicetrapib,这是一种口服低剂量胆固醇酯转移蛋白抑制剂,作为单一疗法和与依折替米贝联合疗法,正在进行各种临床试验,用于降低低密度脂蛋白C和预防重大心血管不良事件。
Recommended Stories
推荐故事
- Get a free copy of the StockNews.com research report on NewAmsterdam Pharma (NAMS)
- Shopify Clears Cup-With-Handle Base: Can Momentum Continue?
- The Future Of E-Commerce: Analysis And New Data
- Chevron Delights Shareholders with $75 Billion in Share Buybacks
- Levi Strauss Is A Good Fit For Income Investors
- 3 Small Caps That Have Big Upside
- 免费获取 StockNews.com 关于 NewAmsterdam Pharma (NAMS) 的研究报告
- Shopify 清理了带手柄的杯子底座:势头能否持续下去?
- 电子商务的未来:分析和新数据
- 雪佛龙通过750亿美元的股票回购使股东感到高兴
- 李维·施特劳斯非常适合收入投资者
- 3 个有很大上升空间的小盘股
Receive News & Ratings for NewAmsterdam Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewAmsterdam Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
接收《新阿姆斯特丹制药日报》的新闻和评级 -在下面输入您的电子邮件地址,即可通过Marketbeat.com的免费每日电子邮件时事通讯接收NewAmsterdam Pharma及相关公司的最新新闻和分析师评级的简明每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧